Search results
3D Ultrastructure of the “Arrhythmogenic” Purkinje Fibre-ventricular Junction in Rabbit Hearts
Author(s):
Shu Nakao
,
Il-Young Oh
,
Luke Stuart
,
et al
Added:
3 years ago
Article
Author(s):
Christos-Konstantinos Antoniou
,
Polychronis Dilaveris
,
Panagiota Manolakou
,
et al
Added:
3 years ago
Ventricular repolarization, as opposed to depolarization, is not a triggered phenomenon following an orderly sequence, hence the dissimilarity between their inscribed electrocardiographic waves; rather, ventricular myocytes repolarize at a time and rate determined by their intrinsic electrophysiological properties (relative concentration of ion channel types and isoforms), as well as by the…
View more
Author(s):
Felipe Martínez
,
Eduardo Perna
,
Sergio V Perrone
,
et al
Added:
3 years ago
Chagas disease was initially described as an endemic health problem in a few countries in South America – mainly Argentina and Brazil – and one of the consequences of the disease, heart damage, made it an interesting issue for healthcare professionals, from epidemiologists to cardiologists.1 Chagas cardiomyopathy (ChCM) is now recognised as a cardiovascular disorder, diagnosed and treated not…
View more
Author(s):
Christopher S Hayward
,
Marc Swartz
Added:
3 years ago
Heart failure is an escalating global pandemic and one of the leading causes of death and disability in the developed world. At present, the incidence of heart failure in the Western world is staggering, affecting approximately 6.5 million people in Europe and 5.8 million people in the US.1–3 Even more alarming is the notion that approximately 10 % of this population suffers from advanced heart…
View more
Author(s):
Jan Peder Amlie
Added:
3 years ago
Conduction and depolarisation in the heart have always interested clinical electrophysiologists. The mapping of conduction is performed more and more in laboratories. Much less attention has been paid to the repolarisation process, although interest in this is increasing.
The repolarisation phase is of great importance for malignant arrhythmias. It is carried by many ionic movements and can be…
View more
Author(s):
Josep Lupón
,
Antoni Bayés-Genís
Added:
3 years ago
The left ventricular ejection fraction (LVEF) – calculated as the stroke volume (end-diastolic volume minus end-systolic volume) divided by the end-diastolic volume – remains the main driver for categorising heart failure (HF) and it is a cornerstone in all randomised clinical trials for patients with HF. Although LVEF has many acknowledged limitations, it remains key for the classification,…
View more
Author(s):
Akihiko Nogami
Added:
3 years ago
No apparent structural abnormality is identified in approximately 10% of all sustained monomorphic ventricular tachycardias (VTs) in the US1 and in 20% of those in Japan.2 These VTs are referred to as ‘idiopathic’. Idiopathic VTs usually occur in specific locations and have specific QRS morphologies, whereas VTs associated with structural heart disease have a QRS morphology that tends to indicate…
View more
Author(s):
Katja Zeppenfeld
,
Martin J Schalij
Added:
3 years ago
Patients with structural heart disease are at risk of ventricular tachycardia (VT), a major cause of sudden cardiac death (SCD) with an incidence of one to two per 1,000 per year.1 The proven life-saving benefit achieved with implantable cardioverter–defibrillators (ICDs) is due to the reduction in SCD. However, several considerations support an important role for therapies that prevent episodes…
View more
Author(s):
Angela Hoye
,
Rodney H Stables
,
Anthony Mathur
,
et al
Added:
1 year ago
BCIS ACI 2023 – Dr Angela Hoye (Hull & East Yorkshire Hospitals, UK), is joined by Dr Rod Stables (Liverpool Heart and Chest Hospital, UK), Dr Anthony Mathur (Barts Health NHS Trust, UK) and Dr Sen Devadathan (Royal Cornwall Hospitals NHS Trust, UK) to have a critical discussion on the BCIS-REVIVED trial and what it means for patients with ischemic left ventricular dysfunction in 2023.
Data…
View more
Author(s):
Dominik Wiedemann
,
Thomas Haberl
,
Julia Riebandt
,
et al
Added:
3 years ago
History of Mechanical Circulatory Support
The first reported clinical use of a left ventricular assist device (LVAD) was by Liotta and Crawford in 1963. Via a left thoracotomy, an intracorporeal pneumatically driven pump was implanted using left atrial inflow and descending thoracic aortic outflow. Despite the successful implantation, the patient died within a short period of time after the…
View more